Dr. Drilon on Immunotherapy in Lung Cancer – OncLive
OncLive |
Dr. Drilon on Immunotherapy in Lung Cancer
OncLive Not every patient is going to benefit from immunotherapy, explains Drilon. Data have recently been discovered that the likelihood of response to single-agent immune checkpoint inhibitors in EGFR-mutant and ALK-rearranged lung cancers is relatively low. |
